Bormioli Pharma increased its North American sales by 47% in 2023
It said the growth was a result of the company's evolving infrastructure and expanded capacity, tailored to meet the demands of the North American pharmaceutical market, including an increased need for pharmaceutical glass vials.
The Italian-headquartered pharmaceutical glass manufacturer said it strengthened its strategic focus on the US market four years ago by establishing a new legal entity and a commercial branch in the US.
Since then it has expanded its on-site commercial team, established a warehouse and designed dedicated product offerings compatible with regional standards.
“For North American customers, this translates into the availability of a reliable and flexible packaging partner that can streamline their purchasing processes while reducing supply chain complexity, shortening their time-to-market and supporting them in the development of high-value projects with local, qualified support.”
The pharmaceutical glass vials market is projected to grow from $12.1 billion in 2023 to $24.1 billion by 2033, expanding at a 7.10% CAGR, driven by rising pharmaceutical product demands.
The US market is one of the major growth contributors (with an expected CAGR of 8.0% in North America for 2023-2028) and there is a high demand for suppliers capable of providing turn-key packaging solutions that meet regional standards, such as the use of glass Type I expansion 33.
Bormioli Pharma recently signed a key contract with a US-based company focused on allergen immunotherapy for the supply of packaging kits for two of its manufacturing sites in the US.
The full packaging kits include aluminium seals, rubber stoppers, Type I moulded glass vials, and Type I tubular glass expansion 33 vials.
Johann Depperschmidt, Bormioli Pharma’s Head of Sales, Americas, said: “To best serve our North American customers, we've adapted our manufacturing processes to produce Type I Glass expansion 33 vials in our European facilities, ensuring robust production and backup.
“We have an on-site, dedicated US sales team and a local warehouse, and we look forward to expanding these resources further in 2024.
“Additionally, we are also collaborating with a US-based sterilisation company to prepare ready-to-use packaging kits – a partnership we believe is a step forward in ensuring that quality healthcare becomes a more accessible reality for people everywhere.”
